2011 European Multidisciplinary Cancer Congress

 
 
 

2011 European Multidisciplinary Cancer Congress

 

Managing breakthrough cancer pain a challenge for nurses

HT Staff Read Article
Published: 10/05/11

nursing_supportive_care.jpg

A survey of European oncology nurses indicates many have difficulty distinguishing breakthrough pain from background pain in cancer patients. This suggests a need for better training as well as a clinical consensus on diagnosis and treatment of breakthrough cancer pain, the researchers say. So they are developing guidelines to help meet this need. The Breakthrough Cancer Pain Initiative—a European Oncology Nursing Society working group—conducted... [Read Article]

Children’s development unaffected by prenatal chemo

HT Staff Read Article
Published: 09/30/11

pregnant_silhouette.jpg

Chemotherapy during pregnancy does not seem to hinder children’s mental or cardiac development, according to new research presented at the 2011 European Multidisciplinary Cancer Congress. The researchers found no difference in growth, general health, development, and congenital malformations between these children and the general population. However, a significant number of the children were delivered preterm. And the team found... [Read Article]

Team advocates smaller, faster cancer trials

HT Staff Read Article
Published: 09/28/11

lab_cancer_research.jpg
Cancer research lab

Smaller, faster cancer trials could speed up the approval of new treatments and improve long-term patient survival, according to a presenter at the 2011 European Multidisciplinary Cancer Congress. The traditional large-scale clinical trial is not always the most effective way of getting new treatments to cancer patients, said Marie-Cécile Le Deley, PhD, of the Institut Gustave-Roussy in Villejuif, France. [Read Article]

Commission assesses cost of cancer care

HT Staff Read Article
Published: 09/27/11

money.jpg

The cost of cancer care in high-income countries is becoming unsustainable, according to an analysis by a commission of experts. The Lancet Oncology Commission is composed of 37 experts from high-income countries. The group performed a comprehensive analysis to determine where these countries have lost their way in managing cancer costs. The findings were presented September 26 at the 2011 European Multidisciplinary Cancer Congress. [Read Article]

Mutation associated with better prognosis in MDS

HT Staff Read Article
Published: 09/27/11

MDS_blood_smear.jpg
Blood smear showing MDS

Geneticists have discovered a gene that is mutated in a significant proportion of people with myelodysplastic syndrome (MDS). Mutations in this gene, SF3B1, tended to be associated with a better prognosis. Elli Papaemmanuil, PhD, of the Wellcome Trust Genome Centre in Cambridge, UK, will present these findings today, September 27, at the 2011 European Multidisciplinary Cancer Congress. [Read Article]

VTE more common than expected among cancer patients

HT Staff Read Article
Published: 09/26/11

thrombus_credit_Kevin MacKenzie_University of Aberdeen_Wellcome Images.jpg
Components of a thrombus
Credit: Kevin MacKenzie
Wellcome Images

An analysis of more than 30,000 cancer patients has shown that venous thromboembolism (VTE) is a more common complication than previously thought. Researchers found that as many as 1 in 5 patients risk developing VTE within a year of receiving treatment for some types of cancers. This finding will be reported today at the 2011 European Multidisciplinary Cancer Congress, which includes the ECCO16, ESMO36, and ESTRO30 congresses. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}